Envestnet Asset Management
ITCI

Envestnet Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Envestnet Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,349
Closed -$838K – 4599
2025
Q1 		$838K Sell
6,349
-125,313
-95% -$15.6M ﹤0.01% 3313
2024
Q4 		$11M Sell
131,662
-2,317
-2% -$190K ﹤0.01% 1574
2024
Q3 		$9.8M Buy
133,979
+7,520
+6% +$565K ﹤0.01% 1646
2024
Q2 		$8.66M Sell
126,459
-2,605
-2% -$181K ﹤0.01% 1651
2024
Q1 		$8.93M Buy
129,064
+721
+0.6% +$49.6K ﹤0.01% 1602
2023
Q4 		$9.19M Buy
128,343
+1,811
+1% +$104K ﹤0.01% 1497
2023
Q3 		$6.59M Buy
126,532
+45,616
+56% +$2.66M ﹤0.01% 1630
2023
Q2 		$5.12M Buy
80,916
+7,869
+11% +$490K ﹤0.01% 1691
2023
Q1 		$3.96M Buy
73,047
+16,192
+28% +$783K ﹤0.01% 1771
2022
Q4 		$3.01M Sell
56,855
-2,080
-4% -$104K ﹤0.01% 1899
2022
Q3 		$2.74M Buy
58,935
+55,308
+1,525% +$2.89M ﹤0.01% 1887
2022
Q2 		$207K Buy
+3,627
New +$206K ﹤0.01% 3582

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Envestnet Asset Management's ITCI Position: Q2 2025 in Review

Envestnet Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 6,349 shares — an estimated $838K sold.

Envestnet Asset Management first reported a position in ITCI in Q2 2022 and held it in 12 quarters. The position peaked at $11M in Q4 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Envestnet Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Envestnet Asset Management sold 6,349 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $838K.
  • Envestnet Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2022 and held it in 12 quarters.
  • Envestnet Asset Management's Intra-Cellular Therapies Inc. position peaked at $11M in Q4 2024.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Envestnet Asset Management's 13F filing for Q2 2025, filed 1 Aug 2025.